Gilead Sciences maximizes data value with Informatica

Gilead has a strategic priority to bring 10+ transformative therapies to patients by 2030. We evaluated Informatica across four categories: user experience, integration, scalability, and very important to us is the cost model as well. So, we picked Informatica. We have deployed an enterprise data platform on AWS. It's adopted by pretty much all the business units in Gilead. So, you can imagine in the full lifecycle of drug development, discovery and commercialization.

We have data from pharmaceutical, development and manufacturing, which includes supply chain and manufacturing, finance, HR, sales, marketing, corporate operations, even business content compliance data, in one platform. So, it lends itself across enterprise use cases because there are no data silos. We have data access layer that provides access to all of the data with fine-grained access control.

So, to us, a single enterprise data platform is not just about cost efficiencies or operational efficiencies. For us, it's a competitive differentiation in the industry. At Gilead, we have adopted data mesh, which is about managing data as a product, domain ownership of data, self-serve data infrastructure and federated data governance.

So, now we use Informatica in our data platform to discover data as well as for our data governance needs. And now, we are moving towards more enterprise master data as well within Informatica. So, I would say that it's a great partnership in terms of working with Informatica and AWS. I can tell you that picking the right data management strategy, along with the right organization model and operating model, and having a data literacy program, a cloud fluency program, is very important for success.